|
Press Releases |
|
|
|
Monday, July 2, 2018 |
|
Eisai to Give Oral Presentation on Results of Phase III Head-to-Head Clinical Study of Lemborexant in Insomnia Disorder |
The symposium will report on the latest data on lemborexant from non-clinical research and clinical studies relating to insomnia, including the results of SUNRISE 1. more info >> |
|
Friday, June 22, 2018 |
|
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN) |
Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. more info >> |
|
アッヴィとエーザイ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」を発売 |
アッヴィ合同会社とエーザイ株式会社は、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」(一般名:アダリムマブ<遺伝子組換え>、以下「ヒュミラ」)の新たな小児用製剤「ヒュミラ(R)皮下注20mgシリンジ0.2mL」について、6月15日に薬価基準に収載されたことを受け、本日、発売したことをお知らせします。 more info >> |
|
エーザイ、「MSCI日本株女性活躍指数(WIN)」の構成銘柄に選定 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび環境、社会、ガバナンス(ESG)投資のために開発された「MSCI 日本株女性活躍指数(WIN)」の構成銘柄に、初めて選定されましたのでお知らせします。本指数は、年金積立金管理運用独立行政法人(GPIF)が、非財務価値であるESGの取り組みに基づいた投資を行うために選定する指数の一つとして採用されています。 more info >> |
|
Thursday, June 21, 2018 |
|
AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL |
AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. more info >> |
|
Thursday, June 14, 2018 |
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research |
Eisai Co., Ltd. announced today that its research subsidiary KAN Research Institute, Inc. has entered into an industry-academia-government joint research agreement with six joint research organizations concerning the "nucleic drug discovery research using novel nucleic acid synthesis and delivery technologies" research project represented by KAN. more info >> |
|
Wednesday, June 13, 2018 |
|
Eisai to Establish New Research Facility "Eisai Center for Genetics Guided Dementia Discovery" in Cambridge, Massachusetts, USA |
Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. more info >> |
|
エーザイ、米国マサチューセッツ州ケンブリッジに新たな研究所Eisai Center for Genetics Guided Dementia Discoveryを設立 |
エーザイ株式会社は、このたび米国マサチューセッツ州ケンブリッジに、認知症領域での革新的創薬を志向したヒト遺伝学(Human Genetics)に基づく認知症神経免疫療法(Immuno-Dementia)にフォーカスした新たな探索研究所(Eisai Center for Genetics Guided Dementia Discovery)を設立することを決定しましたのでお知らせします。 more info >> |
|
Monday, June 11, 2018 |
|
アッヴィ・エーザイ・EAファーマ、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」とオート・インジェクター製剤「ヒュミラ(R)皮下注ペン」を新発売 |
アッヴィ合同会社とエーザイ株式会社およびその消化器事業子会社であるEAファーマ株式会社は、ヒト型抗ヒトTNFαモノクローナル抗体「ヒュミラ(R)」(一般名:アダリムマブ<遺伝子組換え>、以下「ヒュミラ」)のオート・インジェクター製剤「ヒュミラ(R)皮下注40mgペン0.4mL」、および「ヒュミラ(R)皮下注80mgペン0.8mL」について、5月30日に薬価基準に収載されたことを受け、本日、発売したことをお知らせいたします。 more info >> |
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
乐普生物2023年收入快速增长,亏损大幅收窄,ADC进入收获期
Mar 29, 2024 19:48 HKT/SGT
|
|
|
樂普生物2023年收入快速增長,虧損大幅收窄,ADC進入收穫期
Mar 29, 2024 19:41 HKT/SGT
|
|
|
TANAKA Memorial Foundation Announces Recipients of FY2023 Precious Metals Research Grants
Mar 29, 2024 19:19 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 19:02: JST
|
|
|
海通恒信业绩出炉:切实服务实体经济发展 经营质效稳步提升
Mar 29, 2024 18:56 HKT/SGT
|
|
|
海通恒信業績出爐:切實服務實體經濟發展 經營質效穩步提升
Mar 29, 2024 18:52 HKT/SGT
|
|
|
和泓服务:深耕西南区域,业绩稳健增长
Mar 29, 2024 18:43 HKT/SGT
|
|
|
和泓服務:深耕西南區域,業績穩健增長
Mar 29, 2024 18:31 HKT/SGT
|
|
|
MHI Concludes Positive Impact Finance Agreement
Mar 29, 2024 19:20 JST
|
|
|
锅圈:持续扩大业务规模 盈利能力持续增强
Mar 29, 2024 18:10 HKT/SGT
|
|
|
鍋圈:持續擴大業務規模 盈利能力持續增強
Mar 29, 2024 18:07 HKT/SGT
|
|
|
Guoquan: Continuously Expanding the Business Scale While Enhancing Profitability
Mar 29, 2024 18:02 HKT/SGT
|
|
|
Legend Holdings Realized Revenue of RMB436 billion in 2023
Mar 29, 2024 17:55: JST
|
|
|
直面企业发展转型挑战 联想控股如何发展新质生产力
Mar 29, 2024 17:14 HKT/SGT
|
|
|
直面企業發展轉型挑戰 聯想控股如何發展新質生產力
Mar 29, 2024 17:10 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|